Pharmaceutical cooperation between Russian and Chinese companies have been gaining strength over the past several years. Numerous partnerships prove this case. Nonetheless, as the interest towards Russian market grows, more questions on regulatory and procedural aspects of conducting clinical trials, registering new drugs. To that end, the experts from OCT, a leading Russian and Eastern European CRO, will shed light on these questions and cover them during this webinar.